Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival

Abstract excerpt

The number of long-term survivors of high-risk neuroblastoma remains discouraging, with 10-year survival as low as 20%, despite decades of considerable international efforts to improve outcome. Major obstacles remain and include managing resistance to induction therapy, which causes tumor progression and early death in high-risk patients, and managing chemotherapy-resistant relapses, which can occur years after...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Neuroblastoma Research and Treatments
• Share to Protein Degradation and Inhibitors
• Share to Signaling Pathways in Disease